Soman-induced depression of brain activity in TAB-pretreated rats: 2-deoxyglucose study.
Administration of large doses of Soman (2xLD50) to rats protected with TAB, a mixture of trimedoxime (TMB-4), atropine and benactyzine, results in approximately 2-fold reductions of local cerebral glucose utilization (LCGU) in most brain regions. This is in contrast to the marked increase in LCGU that is observed in conjunction with the seizures associated with an LD50 dose of Soman given to unprotected rats. This study reveals that TAB is effective in protecting against Soman-induced seizures, but only at the expense of a severe decrease in LCGU after Soman exposure.
D000818:Animals; D000931:Antidotes / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology*; D001535:Benactyzine / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003847:Deoxyglucose / Q000378:metabolism; D003864:Depression, Chemical; D004338:Drug Combinations / Q000494:pharmacology; D004347:Drug Interactions; D008297:Male; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010091:Oximes / Q000494:pharmacology*; D051381:Rats; D012640:Seizures / Q000139:chemically induced* / Q000378:metabolism; D012999:Soman / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D014289:Trimedoxime / Q000494:pharmacology*
D000931:Antidotes; D004338:Drug Combinations; D009943:Organophosphorus Compounds; D010091:Oximes; D014289:Trimedoxime; D001535:Benactyzine; D001285:Atropine; C040489:TAB antidote; D012999:Soman; D003847:Deoxyglucose